MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584817 | Name: Runcaciguat
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Runcaciguat, also known as BAY 1101042, is a novel, potent, and orally active sGC activator. Runcaciguat activated the sGC reporter cell line with an EC50 value of 11.2 ± 1.0 nM. Pretreatment of the sGC reporter cell line with 30 μM ODQ for 3 h resulted in an increased potency of runcaciguat (EC50 of 2.1 ± 0.07 nM), and treatment of the reporter cells with runcaciguat in combination with the NO donor S-nitroso-N-acetylpenicillamine (SNAP) (10 and 100 nM) showed additive effects. Treatment with runcaciguat resulted in maximal luminescence signals in the range of 50–60% in comparison to the sGC activator cinaciguat. Given the broad impact of oxidative stress in cardiovascular and cardiorenal diseases, runcaciguat might become a new treatment modality for a broad variety of diseases in these indication space but also beyond.

Chemical Structure

Runcaciguat
Runcaciguat
CAS#1402936-61-1

Theoretical Analysis

MedKoo Cat#: 584817

Name: Runcaciguat

CAS#: 1402936-61-1

Chemical Formula: C23H22Cl2F3NO3

Exact Mass: 487.0929

Molecular Weight: 488.33

Elemental Analysis: C, 56.57; H, 4.54; Cl, 14.52; F, 11.67; N, 2.87; O, 9.83

Price and Availability

Size Price Availability Quantity
1mg USD 85.00 Ready to ship
5mg USD 250.00 Ready to ship
10mg USD 450.00 Ready to ship
25mg USD 850.00 Ready to ship
50mg USD 1,450.00 Ready to ship
100mg USD 2,450.00 Ready to ship
200mg USD 3,650.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Runcaciguat; BAY 1101042; BAY-1101042 BAY1101042;
IUPAC/Chemical Name
(3S)-3-{4-chloro-3-[(2S,3R)-2-(4-chlorophenyl)-4,4,4-trifluoro-3-methylbutanamido]phenyl}-3-cyclopropylpropanoic acid
InChi Key
NCRMKIWHFXSBGZ-CNBXIYLPSA-N
InChi Code
InChI=1S/C23H22Cl2F3NO3/c1-12(23(26,27)28)21(14-4-7-16(24)8-5-14)22(32)29-19-10-15(6-9-18(19)25)17(11-20(30)31)13-2-3-13/h4-10,12-13,17,21H,2-3,11H2,1H3,(H,29,32)(H,30,31)/t12-,17+,21+/m1/s1
SMILES Code
O=C(O)C[C@H](C1=CC=C(Cl)C(NC([C@H](C2=CC=C(Cl)C=C2)[C@@H](C)C(F)(F)F)=O)=C1)C3CC3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Generation of cGMP via NO-sensitive soluble guanylyl cyclase (sGC) has been implicated in the regulation of renal functions. Chronic kidney disease (CKD) is associated with decreased NO bioavailability, increased oxidative stress and oxidation of sGC to its haem-free form, apo-sGC. Apo-sGC cannot be activated by NO, resulting in impaired cGMP signalling that is associated with chronic kidney disease progression. sGC activators, which activate apo-sGC independently of NO, increase renal cGMP production under conditions of oxidative stress, thereby improving renal blood flow (RBF) and kidney function.
Biological target:
A novel, potent, and orally active sGC activator.
In vitro activity:
The investigation of the structure-activity relationship allowed to improve potency and multiple solubility, permeability, metabolism, and drug-drug interactions parameters. This program resulted in the discovery of the oral sGC activator runcaciguat (compound 45, BAY 1101042). Runcaciguat is currently investigated in clinical phase 2 studies for the treatment of patients with chronic kidney disease and nonproliferative diabetic retinopathy. Reference: Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den Akker F, Schaefer M, Geiss V, Sandner P, Stasch JP. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). J Med Chem. 2021 May 13;64(9):5323-5344. doi: 10.1021/acs.jmedchem.0c02154. Epub 2021 Apr 19. PMID: 33872507.
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
Soluble in DMSO 0.0 0.00
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 488.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den Akker F, Schaefer M, Geiss V, Sandner P, Stasch JP. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). J Med Chem. 2021 May 13;64(9):5323-5344. doi: 10.1021/acs.jmedchem.0c02154. Epub 2021 Apr 19. PMID: 33872507.
In vitro protocol:
Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den Akker F, Schaefer M, Geiss V, Sandner P, Stasch JP. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). J Med Chem. 2021 May 13;64(9):5323-5344. doi: 10.1021/acs.jmedchem.0c02154. Epub 2021 Apr 19. PMID: 33872507.
In vivo protocol:
TBD
1: Kraehling JR, Benardeau A, Schomber T, Popp L, Vienenkoetter J, Ellinger- Ziegelbauer H, Pavkovic M, Hartmann E, Siudak K, Freyberger A, Hagelschuer I, Mathar I, Hueser J, Hahn MG, Geiss V, Eitner F, Sandner P. The sGC Activator Runcaciguat Has Kidney Protective Effects and Prevents a Decline of Kidney Function in ZSF1 Rats. Int J Mol Sci. 2023 Aug 25;24(17):13226. doi: 10.3390/ijms241713226. PMID: 37686032; PMCID: PMC10488129. 2: Bénardeau A, Kahnert A, Schomber T, Meyer J, Pavkovic M, Kretschmer A, Lawrenz B, Hartmann E, Mathar I, Hueser J, Kraehling JR, Eitner F, Hahn MG, Stasch JP, Sandner P. Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease. Naunyn Schmiedebergs Arch Pharmacol. 2021 Dec;394(12):2363-2379. doi: 10.1007/s00210-021-02149-4. Epub 2021 Sep 22. PMID: 34550407; PMCID: PMC8592982. 3: Hahn MG, Lampe T, El Sheikh S, Griebenow N, Woltering E, Schlemmer KH, Dietz L, Gerisch M, Wunder F, Becker-Pelster EM, Mondritzki T, Tinel H, Knorr A, Kern A, Lang D, Hueser J, Schomber T, Benardeau A, Eitner F, Truebel H, Mittendorf J, Kumar V, van den Akker F, Schaefer M, Geiss V, Sandner P, Stasch JP. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042). J Med Chem. 2021 May 13;64(9):5323-5344. doi: 10.1021/acs.jmedchem.0c02154. Epub 2021 Apr 19. PMID: 33872507. 4: Nelissen E, Possemis N, Van Goethem NP, Schepers M, Mulder-Jongen DAJ, Dietz L, Janssen W, Gerisch M, Hüser J, Sandner P, Vanmierlo T, Prickaerts J. The sGC stimulator BAY-747 and activator runcaciguat can enhance memory in vivo via differential hippocampal plasticity mechanisms. Sci Rep. 2022 Mar 4;12(1):3589. doi: 10.1038/s41598-022-07391-1. PMID: 35246566; PMCID: PMC8897390. 5: Sandner P, Follmann M, Becker-Pelster E, Hahn MG, Meier C, Freitas C, Roessig L, Stasch JP. Soluble GC stimulators and activators: Past, present and future. Br J Pharmacol. 2024 Nov;181(21):4130-4151. doi: 10.1111/bph.15698. Epub 2021 Dec 1. PMID: 34600441. 6: Zhong C, Xu M, Boral S, Summer H, Lichtenberger FB, Erdoğan C, Gollasch M, Golz S, Persson PB, Schleifenbaum J, Patzak A, Khedkar PH. Age Impairs Soluble Guanylyl Cyclase Function in Mouse Mesenteric Arteries. Int J Mol Sci. 2021 Oct 22;22(21):11412. doi: 10.3390/ijms222111412. PMID: 34768842; PMCID: PMC8584026. 7: Stehle D, Xu MZ, Schomber T, Hahn MG, Schweda F, Feil S, Kraehling JR, Eitner F, Patzak A, Sandner P, Feil R, Bénardeau A. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney. Br J Pharmacol. 2022 Jun;179(11):2476-2489. doi: 10.1111/bph.15586. Epub 2021 Jul 3. PMID: 34096053; PMCID: PMC9292672. 8: Patel R, Fu Y, Khang S, Benardeau AM, Thomson SC, Vallon V. Responses in Blood Pressure and Kidney Function to Soluble Guanylyl Cyclase Stimulation or Activation in Normal and Diabetic Rats. Nephron. 2023;147(5):281-300. doi: 10.1159/000526934. Epub 2022 Oct 20. PMID: 36265461; PMCID: PMC10115913. 9: Friebe A, Kraehling JR, Russwurm M, Sandner P, Schmidtko A. The 10th International Conference on cGMP 2022: recent trends in cGMP research and development-meeting report. Naunyn Schmiedebergs Arch Pharmacol. 2023 Aug;396(8):1669-1686. doi: 10.1007/s00210-023-02484-8. Epub 2023 Apr 20. PMID: 37079081; PMCID: PMC10338386.